The global surgical mesh industry is booming with a value of $650 million in 2024 – projected to surge past $950 million by 2030.

Behind the billion-dollar glossy forecasts we’re extremely concerned over global expansion of mesh use with no long term outcome logging – leading to safety concerns for millions of unsuspecting patients.

Driven by aggressive marketing, we fear traditional surgery skills are being lost. For example hernia mesh is promoted over traditional native tissue Shouldice hernia repairs and prolapse mesh and bladder mesh slings are sold as a quick fix with shorter recovery times compared to the tried and tested operations to treat these conditions.

This, despite vaginal prolapse mesh being banned in the UK. America, Australia and New Zealand and bladder mesh slings suspended across the UK owing to the risk of unacceptable life changing complications.

America, Latin America, and Asia

According to a new 500-page report by Pristine Market Insights, the surgical mesh market is rapidly penetrating emerging regions:

• Asia Pacific now accounts for 30% of global volume, due to growing healthcare infrastructure.
• Latin America has seen a 14% increase in hospital capacity, unlocking demand for synthetic and biologic mesh.
• In North America, insurance now covers up to 90% of mesh costs, fuelling a 12% rise in surgeon adoption.
• Even the Middle East is joining the trend, with insurance coverage expanding to 75% of device costs, boosting regional revenues by 9% annually.

Innovation is just a word for new

The industry is touting cutting-edge advancements which they celebrate as innovation. But innovation simply means new. It doesn’t necessarily mean better! It means it has not been trialled long term. For example:

• 3D-printed, patient-specific meshes now make up 10% of custom orders.
• Bioactive coatings on 65% of new meshes aim to reduce fibrosis and improve healing.
• Smart meshes with embedded biosensors are being tested to detect inflammation in real time.

Mesh concerns

We are deeply concerned about the aggressive, glossy marketing tactics used to push mesh products into new markets.

• Patient safety is being sidelined in favour of profit.
• Emerging markets may lack regulatory oversight needed to protect patients.
• Postoperative complications are underreported, especially in regions with limited follow-up care.
• We need greater transparency, robust clinical trials, and patient-centered regulation before mesh products are rolled out globally.

While the surgical mesh market is poised for massive growth, we urge caution. As companies race to capture new markets, the question remains … are patients being protected or pushed aside in the name of profits?